“…[2,56,75,8,99] Stem cell-derived CMs have emerged as one of the most attractive cellular sources for the rescue of damaged cardiac tissue based on cell therapy, e.g., mouse and human iPS-derived functional CMs, [29,86,100] Gao et al proposed a protocol for the preparation of human cardiac patches (hCMPs), which consisted of derivatizing hiPS into CMs, ECs, and smooth muscle cells, respectively, and mixed them to form hCMPs. [58] In a guinea pig MI model, implantation of an hiPS-derived engineered heart tissue patch showed muscularization of scarring, improvement in left ventricular ejection fraction (LVEF), and reduction in left ventricular end-diastolic diameter. [57] In one study, Chow et al [31] loaded iPSC-derived CMs onto polyethylene glycol (PEG) hydrogel and injected them into MI rats to evaluate their therapeutic effect.…”